High Expression of Neuropeptide Y Receptors in Tumors of the Human Adrenal Gland and Extra-Adrenal Paraganglia
Reads0
Chats0
TLDR
These receptor data suggest a role of NPY in adrenal cortical tumors and, together with the strong NPY innervation of the cortex, a physiologic role in the adrenal gland, mediated by Y1 receptors.Abstract:
Purpose: Recently, a role of neuropeptide Y (NPY) in tumor biology was suggested based on the high density of NPY receptors in breast and ovarian cancers. The high frequency of NPY receptors in steroid hormone-producing ovarian sex cord-stromal tumors, together with the known influence of NPY on steroid hormone and catecholamine secretion in the rodent adrenal gland, led to the investigation of NPY receptor expression in the human adrenal gland and related tumors. Experimental Design: Fifteen adrenal cortical tumors, 20 paragangliomas, 23 pheochromocytomas, 20 neuroblastomas, and 8 normal adrenal glands were investigated by in vitro NPY receptor autoradiography using 125 I-labeled peptide YY in competition experiments with receptor subtype selective analogs. Results: Ninety three percent of cortical tumors express Y1, 35% of pheochromocytomas and 61% of paragangliomas express Y1 and Y2, and 90% of neuroblastomas express Y2 receptors. The NPY receptors in pheochromocytomas, paragangliomas, and neuroblastomas are often expressed concomitantly with the NPY hormone detected immunohistochemically. The adrenal cortex strongly expresses Y1, whereas no NPY receptors are found in the adrenal medulla. Conclusions: These receptor data suggest a role of NPY in adrenal cortical tumors and, together with the strong NPY innervation of the cortex, a physiologic role in the adrenal gland, mediated by Y1 receptors. These NPY receptors are a potential new molecular target for the therapy of malignant tumors.read more
Citations
More filters
Journal ArticleDOI
Imaging of neuroendocrine tumors.
TL;DR: Significant improvements have been made during the past few years with the development of highly specific radiopharmaceuticals for PET studies that reflect the different metabolic pathways of NETs, such as glucose metabolism, the uptake of hormone precursors, and the synthesis, storage, and release of hormones.
Journal ArticleDOI
NPY receptors in human cancer: a review of current knowledge
Meike Körner,Jean Claude Reubi +1 more
TL;DR: NPY receptors are novel and promising candidates in this field and may be targeted with NPY analogs coupled with adequate radionuclides or cytotoxic agents for a scintigraphic tumor imaging and/or tumor therapy.
Journal ArticleDOI
Radiometallated peptides for molecular imaging and targeted therapy
TL;DR: An overview of the chemical strategies explored to improve the biological performance of different families of radiometallated peptides for nuclear molecular imaging and/or targeted radionuclide tumor therapy is provided.
Journal ArticleDOI
Neuropeptide Y Y2 receptor in health and disease
TL;DR: Property of the receptor and of Y2 agonists are considered and reviewed in connection to the negative regulation of transmitter release, feeding, mood and social behavior and the possible involvement of the Y2 receptor in diabetes, carcinogenesis and bone formation is reviewed.
Journal ArticleDOI
Incorporation of ortho-carbaboranyl-Nε-modified L-lysine into neuropeptide Y receptor Y1- and Y2-selective analogues.
TL;DR: Internalization studies revealed excellent and receptor subtype specific uptake of the conjugates into respective cells and nanomolar affinity and activity of the modified analogues despite of the large carbaborane cluster.
References
More filters
Journal ArticleDOI
World Health Organization classification of tumors.
Paul Kleihues,Leslie H. Sobin +1 more
TL;DR: World Health Organization Collaborating Center for International Histological Classification of Tu-mors, Armed Forces Institute of Pathology, Wash-ington, DC.
Journal ArticleDOI
Peptide receptors as molecular targets for cancer diagnosis and therapy.
TL;DR: The paradigmatic peptide somatostatin and its receptors are extensively reviewed in the light of in vivo targeting of neuroendocrine tumors and the role of the more recently described targeting peptides vasoactive intestinal peptides, gastrin-releasing peptide, and cholecystokinin/gastrin is discussed.
Journal Article
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
Martin C. Michel,Annette G. Beck-Sickinger,Helen M. Cox,Henri Doods,Herbert Herzog,Dan Larhammar,Rémi Quirion,Thue W. Schwartz,Thomas C. Westfall +8 more
TL;DR: Based on structural and evolutionary criteria, neuropeptide Y (NPY)b, peptide YY (PYY) and pancreatic polypetide (PP) are closely related polypeptides that share considerable amino acid homology, amidated C-terminal ends, and the same structure.
Journal Article
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Christian Waldherr,Miklos Pless,Helmut R. Maecke,Tilmann Schumacher,Armin Crazzolara,Egbert U. Nitzsche,Andreas R. Haldemann,Jan Mueller-Brand +7 more
TL;DR: High-dose targeted radiotherapy with 7.4 GBq/m(2) of the radiolabeled somatostatin analog (90)Y-DOTATOC is a well-tolerated treatment for neuroendocrine tumors, with remarkable clinical benefit and objective response.
Journal ArticleDOI
Somatostatin Receptor Scintigraphy: Its Sensitivity Compared with That of Other Imaging Methods in Detecting Primary and Metastatic Gastrinomas: A Prospective Study
Fathia Gibril,James C. Reynolds,John L. Doppman,Clara C. Chen,David Venzon,B Termanini,H C Weber,Chip Stewart,Robert T. Jensen +8 more
TL;DR: It is difficult for the practitioner to define the potential role of somatostatin receptor scintigraphy in the evaluation of a patient with a gastroenteropancreatic syndrome because many studies do not provide the data needed and it remains unclear whether additional localization studies are helpful.